Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Heron Therapeutics (HRTX) Return on Sales (2016 - 2025)

Heron Therapeutics (HRTX) has disclosed Return on Sales for 13 consecutive years, with 0.0% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Return on Sales fell 10.0% year-over-year to 0.0%, compared with a TTM value of 0.02% through Dec 2025, up 6.0%, and an annual FY2025 reading of 0.07%, up 3.0% over the prior year.
  • Return on Sales was 0.0% for Q4 2025 at Heron Therapeutics, up from 0.11% in the prior quarter.
  • Across five years, Return on Sales topped out at 0.1% in Q4 2024 and bottomed at 2.69% in Q2 2021.
  • Average Return on Sales over 5 years is 1.04%, with a median of 0.74% recorded in 2022.
  • The sharpest move saw Return on Sales tumbled -53bps in 2021, then soared 191bps in 2022.
  • Year by year, Return on Sales stood at 2.59% in 2021, then soared by 74bps to 0.68% in 2022, then surged by 56bps to 0.3% in 2023, then skyrocketed by 134bps to 0.1% in 2024, then plummeted by -99bps to 0.0% in 2025.
  • Business Quant data shows Return on Sales for HRTX at 0.0% in Q4 2025, 0.11% in Q3 2025, and 0.04% in Q2 2025.